✦ LIBER ✦

Prodrug Mono therapy: synthesis and biological evaluation of an etoposide glucuronide-prodrug

✍ Scribed by Frédéric Schmidt; Claude Monneret

Book ID: 108479330
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 222 KB
Volume: 11
Category: Article
ISSN: 0968-0896
DOI: 10.1016/s0968-0896(03)00108-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Synthesis and biological evaluations of

Synthesis and biological evaluations of a monomethylauristatin E glucuronide prodrug for selective cancer chemotherapy

✍ Legigan, Thibaut; Clarhaut, Jonathan; Renoux, Brigitte; Tranoy-Opalinski, Isabel 📂 Article 📅 2013 🏛 Elsevier Science 🌐 French ⚖ 547 KB

Synthesis and biological evaluation of p

Synthesis and biological evaluation of prodrugs of zidovudine

✍ Aggarwal, Sunil K.; Gogu, Sudhir R.; Rangan, S. R. S.; Agrawal, Krishna C. 📂 Article 📅 1990 🏛 American Chemical Society 🌐 English ⚖ 814 KB

Synthesis and Biological Evaluation of a

Synthesis and Biological Evaluation of a Cytarabine Phosphoramidate Prodrug

✍ Tobias, Sandra C.; Borch, Richard F. 📂 Article 📅 2003 🏛 American Chemical Society 🌐 English ⚖ 53 KB

Synthesis, Crystallization, and Biologic

Synthesis, Crystallization, and Biological Evaluation of an Orally Active Prodrug of Gemcitabine

✍ Bender, David M.; Bao, Jingqi; Dantzig, Anne H.; Diseroad, William D.; Law, Kevi 📂 Article 📅 2009 🏛 American Chemical Society 🌐 English ⚖ 952 KB

Synthesis and biological evaluation of p

Synthesis and biological evaluation of phosphoramide mustard (PM) prodrugs

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 345 KB

Asymmetric Synthesis and Biological Eval

Asymmetric Synthesis and Biological Evaluation of Glycosidic Prodrugs for a Selective Cancer Therapy

✍ Lutz F. Tietze; J. Marian von Hof; Birgit Krewer; Michael Müller; Felix Major; H 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 390 KB 👁 1 views

## Abstract A severe limitation in cancer therapy is the often insufficient differentiation between malign and benign tissue using known chemotherapeutics. One approach to decrease side effects is antibody‐directed enzyme prodrug therapy (ADEPT). We have developed new glycosidic prodrugs such as (−